Microcap Ledger Connect Biopharma Holdings Ltd $CNTB
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- San Diego, CA
- Fiscal year end
- December 31
- Shares outstanding
- 62,974,309 [10-Q 2026-08-12]
What the company doesAI summary of filing
Connect Biopharma is a clinical-stage biopharmaceutical company developing rademikibart, a human monoclonal antibody targeting IL-4 receptor alpha for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The company is advancing two Phase 2 trials evaluating rademikibart for acute exacerbations of asthma and COPD, with topline data expected in mid-2026, and has also completed Phase 2 trials in chronic asthma and atopic dermatitis. The company generates revenue through a licensing agreement with Simcere Pharmaceutical for Greater China rights, having received $27.5 million in upfront and milestone payments to date, and is eligible for up to $110 million in additional milestones plus royalties. Connect is pre-revenue from product sales and depends on external capital for continued development. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $2.94M | −$36.68M | −$31.93M | $27.02M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | $64.0K | −$55.48M | −$51.21M | $38.34M | [10-K 2026-03-31] |
| FY ended Dec 2024 | $26.03M | −$15.63M | −$23.61M | $78.23M | [10-K 2026-03-31] |
- Quarterly cash burn
- −$15.96M
- Cash runway Estimate
- ~5.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2023-12-31 | 55,102,954 | [20-F 2024-04-16] |
| 2025-03-21 | 55,349,208 | [10-K 2025-03-31] |
| 2025-04-30 | 55,561,056 | [10-Q 2025-05-15] |
| 2025-07-31 | 55,721,657 | [10-Q 2025-08-13] |
| 2025-10-31 | 55,903,513 | [10-Q 2025-11-12] |
| 2026-03-26 | 56,521,282 | [10-K 2026-03-31] |
| 2026-04-30 | 62,963,853 | [10-Q 2026-05-12] |
| 2026-07-31 | 62,974,309 | [10-Q 2026-08-12] |
- Shelf registration
- F-3 filed 2026-05-15; declared effective 2026-06-01 [F-3 2026-05-15]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-30 | Xanthopoulos Kleanthis Gabriel | grant | 5,000 | — | [4 2026-10-01] |
| 2026-09-30 | Liu Jean I | grant | 8,984 | — | [4 2026-10-01] |
| 2026-06-30 | Xanthopoulos Kleanthis Gabriel | grant | 3,738 | — | [4 2026-07-01] |
| 2026-06-30 | Liu Jean I | grant | 6,718 | — | [4 2026-07-01] |
| 2026-05-29 | Huang James | buy | 150,000 | $2.48 | [4 2026-06-02] |
| 2026-03-31 | Xanthopoulos Kleanthis Gabriel | grant | 2,816 | — | [4 2026-04-02] |
| 2026-03-31 | Liu Jean I | grant | 5,061 | — | [4 2026-04-02] |
| 2026-03-31 | Huang James | buy | 1,160,000 | $3.45 | [4 2026-04-01] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-06 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-09-30 | 8-K | Regulation FD disclosure; Other events |
| 2026-09-15 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Results of operations |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Results of operations |
| 2026-04-23 | 8-K | Regulation FD disclosure; Other events |
| 2026-04-14 | 13G | Beneficial ownership report (5%+ holder) |
Alerts for $CNTB
Email me when Connect Biopharma Holdings Ltd files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.